Entheon Biomedical Corp. (ENBI.CN)

CAD 0.12

(-17.86%)

Revenue Summary of Entheon Biomedical Corp.

  • Entheon Biomedical Corp.'s latest annual revenue in 2023 was 250.32 Thousand CAD , up 31.97% from previous year.
  • Entheon Biomedical Corp.'s latest quarterly revenue in 2024 Q3 was - CAD , down 0.0% from previous quarter.
  • Entheon Biomedical Corp. reported a annual revenue of 189.67 Thousand CAD in annual revenue 2022, up 775.3% from previous year.
  • Entheon Biomedical Corp. reported a annual revenue of 21.67 Thousand CAD in annual revenue 2021, down 0.0% from previous year.
  • Entheon Biomedical Corp. reported a quarterly revenue of - CAD for 2024 Q1, down 0.0% from previous quarter.
  • Entheon Biomedical Corp. reported a quarterly revenue of - CAD for 2024 Q3, down 0.0% from previous quarter.

Annual Revenue Chart of Entheon Biomedical Corp. (2023 - 2015)

Historical Annual Revenue of Entheon Biomedical Corp. (2023 - 2015)

Year Revenue Revenue Growth
2023 250.32 Thousand CAD 31.97%
2022 189.67 Thousand CAD 775.3%
2021 21.67 Thousand CAD 0.0%
2020 - CAD 0.0%
2019 - CAD 0.0%
2018 - CAD 0.0%
2017 - CAD 0.0%
2016 - CAD 0.0%
2015 - CAD 0.0%

Peer Revenue Comparison of Entheon Biomedical Corp.

Name Revenue Revenue Difference
Algernon Pharmaceuticals Inc. - CAD -Infinity%
Asep Medical Holdings Inc 21.14 Thousand CAD -1084.12%
BetterLife Pharma Inc. - CAD -Infinity%
BioVaxys Technology Corp. - CAD -Infinity%
ChitogenX Inc. - CAD -Infinity%
Rapid Dose Therapeutics Corp. 1.02 Million CAD 75.469%
Defence Therapeutics Inc. - CAD -Infinity%
Gemina Laboratories Ltd. - CAD -Infinity%
Glow Lifetech Corp. 43.93 Thousand CAD -469.809%
Lexston Life Sciences Corp. - CAD -Infinity%
Pharmala Biotech Holdings Inc. 532 Thousand CAD 52.947%
Doseology Sciences Inc. 98.52 Thousand CAD -154.078%
MYND Life Sciences Inc. - CAD -Infinity%
Nova Mentis Life Science Corp. 28.34 Thousand CAD -783.098%
PharmaTher Holdings Ltd. - CAD -Infinity%
PreveCeutical Medical Inc. - CAD -Infinity%
Telescope Innovations Corp. 595.39 Thousand CAD 57.957%